<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Durvalumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Durvalumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Durvalumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="113073" href="/d/html/113073.html" rel="external">see "Durvalumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F50081302"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Imfinzi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872276"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imfinzi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50027744"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anti-PD-L1 Monoclonal Antibody;</li>
<li>
                        Antineoplastic Agent, Immune Checkpoint Inhibitor;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F50135396"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26d3316d-4c08-4b75-8edd-b740ae5ff2a7">Biliary tract cancer, locally advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, locally advanced or metastatic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients ≥30 kg: </i>
<b>IV:</b> 1,500 mg once every 3 weeks (in combination with gemcitabine and cisplatin) for up to 8 cycles, followed by 1,500 mg once every 4 weeks as a single agent until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Oh.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Oh.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients &lt;30 kg: </i>
<b>IV: </b>20 mg/<b>kg</b> once every 3 weeks (in combination with gemcitabine and cisplatin) for up to 8 cycles, followed by 20 mg/<b>kg</b> once every 4 weeks as a single agent until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bea91e4d-a7de-4963-92b0-ea5efc19008f">Hepatocellular carcinoma, unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, unresectable:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients ≥30 kg: </i>
<b>IV:</b> 1,500 mg on day 1 of cycle 1 (in combination with tremelimumab), followed by 1,500 mg once every 4 weeks as a single agent until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Abou-Alfa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Abou-Alfa.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients &lt;30 kg: </i>
<b>IV: </b>20 mg/<b>kg</b> on day 1 of cycle 1 (in combination with tremelimumab), followed by 20 mg/<b>kg</b> once every 4 weeks as a single agent until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16eb6f9b-a39d-46ad-b495-cccbfeba4ee8">Non–small cell lung cancer, stage 3, unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, stage 3, unresectable:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In the clinical trial, durvalumab was initiated within 6 weeks after chemoradiotherapy; treatment was continued beyond 12 months if disease control was achieved at the end of 12 months but then progressed during follow-up (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885881','lexi-content-ref-30280658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885881','lexi-content-ref-30280658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients ≥30 kg:</i>
<b>IV: </b>10 mg<b>/kg</b> once every 2 weeks <b>or </b>1,500 mg once every 4 weeks; continue until disease progression or unacceptable toxicity or a maximum of 12 months.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients &lt;30 kg:</i>
<b>IV: </b>10 mg/<b>kg</b> once every 2 weeks; continue until disease progression or unacceptable toxicity or a maximum of 12 months.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ac928cc-a5fe-47d5-847f-e5abed320440">Non–small cell lung cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic: Note:</b> Weigh patients prior to each durvalumab infusion. Durvalumab dosing interval varies based on cycle of therapy. Refer to protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>) for further information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Non-squamous</b> tumor histology:</i> Chemotherapy consisted of up to 4 cycles of carboplatin in combination with paclitaxel (protein bound) <b>or</b> pemetrexed in combination with either carboplatin or cisplatin. If the pemetrexed-based chemotherapy regimen is utilized, may administer optional pemetrexed maintenance therapy (in combination with durvalumab) starting at week 12 and continuing until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Squamous</b> tumor histology:</i> Chemotherapy consisted of up to 4 cycles of carboplatin in combination with paclitaxel (protein bound) <b>or</b> gemcitabine in combination with either carboplatin or cisplatin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Non-squamous or squamous tumor histologies:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients ≥30 kg: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycles 1 through 4: </i>
<b>IV:</b> 1,500 mg on day 1 every 3 weeks for cycles 1 through 4 (in combination with tremelimumab and platinum-based chemotherapy).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 5:</i>
<b>IV: </b>1,500 mg on day 1. No tremelimumab dose is administered; refer to tremelimumab monograph for tremelimumab dosing schedule. The durvalumab dosing interval changes from every 3 weeks to every 4 weeks starting at cycle 5 (cycle 5 is administered at week 12).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 6: </i>
<b>IV</b>: 1,500 mg on day 1 (in combination with tremelimumab), beginning 4 weeks after the previous durvalumab dose (cycle 6 is administered at week 16).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 7 and beyond</i>: <b>IV</b>: 1,500 mg on day 1 every 4 weeks until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients &lt;30 kg: </i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycles 1 through 4: </i>
<b>IV:</b> 20 mg/kg on day 1 every 3 weeks for cycles 1 through 4 (in combination with tremelimumab and platinum-based chemotherapy).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 5:</i>
<b>IV:</b> 20 mg/kg on day 1. No tremelimumab dose is administered; refer to tremelimumab monograph for tremelimumab dosing schedule. The durvalumab dosing interval changes from every 3 weeks to every 4 weeks starting at cycle 5 (cycle 5 is administered at week 12).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 6: </i>
<b>IV:</b> 20 mg/kg on day 1 (in combination with tremelimumab), beginning 4 weeks after the previous durvalumab dose (cycle 6 is administered at week 16).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cycle 7 and beyond</i>: <b>IV</b>: 20 mg/kg on day 1 every 4 weeks until disease progression or unacceptable toxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c88caf76-c889-4e40-ac97-066402923404">Small cell lung cancer, extensive stage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, extensive stage:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients ≥30 kg:</i>
<b>IV: </b>1,500 mg once every 3 weeks (in combination with etoposide and either carboplatin or cisplatin) for 4 cycles, followed by 1,500 mg once every 4 weeks as a single agent until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31590988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31590988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients &lt;30 kg: </i>
<b>IV: </b>20 mg/<b>kg</b> once every 3 weeks (in combination with etoposide and either carboplatin or cisplatin) for 4 cycles, followed by 10 mg/<b>kg</b> once every 2 weeks as a single agent until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991765"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 89 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, there is no clinically relevant effect on pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 15 to 29 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (effect on durvalumab pharmacokinetics is unknown).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Kidney toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated nephritis with kidney dysfunction:</i> If durvalumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold durvalumab; resume durvalumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue durvalumab.</p></div>
<div class="block doha drugH1Div" id="F50989036"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (bilirubin ≤3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling; however, there is no clinically relevant effect on pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (bilirubin &gt;3 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (effect on durvalumab pharmacokinetics is unknown).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If durvalumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to ≤ grade 1, then follow with a corticosteroid taper. Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>without</b> tumor involvement of the liver:</i></p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;3 up to 8 × ULN or total bilirubin &gt;1.5 up to 3 × ULN: Withhold durvalumab treatment. Resume durvalumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">AST or ALT &gt;8 × ULN or total bilirubin &gt;3 × ULN: Discontinue durvalumab permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immune-mediated hepatitis <b>with </b>tumor involvement of the liver:</i>
<b>Note: </b>If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:8em;">If baseline AST or ALT is &gt;1 up to 3 × ULN and increases to &gt;5 up to 10 × ULN or baseline AST or ALT is &gt;3 up to 5 × ULN and increases to &gt;8 up to 10 × ULN: Withhold durvalumab treatment. Resume durvalumab treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:8em;">If AST or ALT increases to &gt;10 × ULN or total bilirubin increases to &gt;3 × ULN: Discontinue durvalumab permanently.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Additional</i>
<i> recommendations:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 2 immune-mediated hepatitis:</i> Withhold immune checkpoint inhibitor (ICI); if no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Grade 3 or 4 immune-mediated hepatitis:</i> Withhold ICI; initiate corticosteroids (methylprednisolone 1 to 2 mg/kg or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34709662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34709662'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F57498128"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer </i>
<i>with a BMI ≥30 kg/m<sup>2</sup></i>
<i>:</i> The dosing in the FDA-approved prescribing information should be followed in all patients, regardless of obesity status. If a patient with a BMI ≥30 kg/m<sup>2 </sup>experiences high-grade toxicity from systemic anticancer therapy, the same dosage modification recommendations should be followed for all patients, regardless of obesity status (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F50135400"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> No dose reduction for durvalumab is recommended. Other concomitant combination anticancer therapies may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immune-mediated adverse reactions (general information):</b> Withhold durvalumab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue durvalumab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or inability to reduce corticosteroid dose to prednisone ≤10 mg/day (or equivalent) within 12 weeks of initiating corticosteroids. In general, if durvalumab treatment interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1; upon improvement to ≤ grade 1, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with systemic corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Additional management </i></b>
<b>
<i>recommendations:</i></b> Consider withholding checkpoint inhibitor therapy for most grade 2 toxicities and resume when symptoms and/or lab values resolve to ≤ grade 1; systemic corticosteroids (initial dose of 0.5 to 1 mg/kg/day prednisone [or equivalent]) may be administered if indicated for grade 2 toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Refer to guideline for further information regarding management of immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:center;">
<b>Durvalumab Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Durvalumab dosage modification</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>SJS = Stevens-Johnson Syndrome; TEN = toxic epidermal necrolysis; DRESS = drug rash with eosinophilia and systemic symptoms.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Refer to prednisone monograph for tapering recommendations when used for immune-mediated adverse reactions associated with checkpoint inhibitor therapy.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Immune-mediated adverse reactions</i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Mild or moderate nonexfoliative rash</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">May be managed with topical emollients and/or topical corticosteroids.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Exfoliative dermatologic conditions: Suspected SJS, TEN, or DRESS<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold durvalumab; resume with complete or partial resolution of toxicity (to grade 0 or 1) after corticosteroid taper.<sup>b</sup> Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Confirmed SJS, TEN, or DRESS<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;text-align:left;">Endocrinopathies</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold durvalumab until clinically stable or permanently discontinue (depending on severity).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Adrenal insufficiency, ≥ grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate symptomatic management (including hormone replacement as clinically indicated).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Diabetes, type 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate insulin as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypophysitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold or discontinue durvalumab (depending on severity). Initiate hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hyperthyroidism</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypothyroidism</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;text-align:left;">GI toxicity: Colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold durvalumab; resume with complete or partial resolution of toxicity (to grade 0 or 1) after corticosteroid taper.<sup>b</sup> Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold durvalumab; resume with complete or partial resolution of toxicity (to grade 0 or 1) after corticosteroid taper.<sup>b</sup> Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3: Durvalumab in combination with tremelimumab</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">GI toxicity: Intestinal perforation</p></td>
<td align="center">
<p style="text-indent:0em;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Neurologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold durvalumab; resume with complete or partial resolution of toxicity (to grade 0 or 1) after corticosteroid taper.<sup>b</sup> Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ocular disorders: Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold durvalumab; resume with complete or partial resolution of toxicity (to grade 0 or 1) after corticosteroid taper.<sup>b</sup> Permanently discontinue durvalumab if no complete or partial response within 12 weeks of initiating corticosteroids, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Other adverse reactions</i></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Infusion reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Interrupt or slow the rate of durvalumab infusion. Consider premedication(s) with subsequent doses.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue durvalumab.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F50135397"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50087901"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (12%), skin rash (23%; including dermatitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperglycemia (52%), hyperkalemia (32%), hypocalcemia (46%), hyponatremia (33%), hypothyroidism (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (43%; grades 3/4: 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (24%), increased serum alanine aminotransferase (39%), increased serum aspartate aminotransferase (36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (34%; including asthenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (≤40%), pneumonia (17%), pneumonitis (≤34%; includes pulmonary fibrosis), productive cough (≤40%), radiation pneumonitis (≤34%), upper respiratory tract infection (26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Night sweats (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Increased susceptibility to infection (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Voice disorder (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency, hypoparathyroidism, hypophysitis, pituitary insufficiency</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, hemolytic anemia, hemophagocytic lymphohistiocytosis, lymphadenitis (histiocytic necrotizing lymphadenitis [Kikuchi lymphadenitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (may be neutralizing), organ transplant rejection (solid)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Guillain-Barre syndrome, meningitis, myasthenia (myasthenic syndrome), neuropathy (autoimmune), paresis (nerve)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Polymyositis, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Iritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephritis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Myocarditis (Cham 2021), pericarditis (Landman 2021), vasculitis (Casafont-Sole 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pemphigoid (SITC [Brahmer 2021]), Stevens-Johnson syndrome (SITC [Brahmer 2021]), toxic epidermal necrolysis (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetic ketoacidosis (Patel 2019), hyperthyroidism (Antonia 2017), thyroiditis (Mengibar 2019), type 1 diabetes mellitus (Antonia 2017; Mengibar 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis (SITC [Brahmer 2021]), cholecystitis (SITC [Brahmer 2021]), colitis (enterocolitis) (Huang 2021), constipation (Antonia 2017), decreased appetite (Antonia 2017), diarrhea (Powles 2020), duodenitis (Huang 2021), esophagitis (SITC [Brahmer 2021]), gastritis (Otohara 2022), increased serum amylase (Powles 2020), increased serum lipase (Powles 2020), nausea (SITC [Brahmer 2021]), pancreatitis (Malet 2022), xerostomia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Immune thrombocytopenia (Dougherty 2021), lymphadenopathy (sarcoid-like, pulmonary) (Sanderson 2020), neutropenia (SITC [Brahmer 2021]), pure red cell aplasia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (Landman 2021), hepatotoxicity (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (including severe infusion-related reaction) (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Sarcoidosis (Antonia 2017), Sjögren disease (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease (Liu 2021), encephalitis (Shionoya 2021), myasthenia gravis (including exacerbation of myasthenia gravis) (Abidoye 2022; Cham 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (SITC [Brahmer 2021]), arthritis (SITC [Brahmer 2021]), myalgia (SITC [Brahmer 2021]), myelitis (Wang 2022), myositis (Cham 2021), polymyalgia rheumatica (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (SITC [Brahmer 2021]), uveitis (Vrabic 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Powles 2020; SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (Antonia 2017)</p></div>
<div class="block coi drugH1Div" id="F50027747"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to durvalumab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F50135364"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse reactions (immune-mediated): PD-1/PD-L1 blockers (including durvalumab) remove immune response inhibition, thus potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Severe and fatal immune-mediated adverse reactions may occur in any organ system or tissue. Reactions generally occur during treatment (may occur at any time after durvalumab initiation); reactions may also occur after durvalumab discontinuation. Early identification and management of immune-mediated reactions are necessary to ensure safe use of durvalumab. If suspected immune-mediated reactions occur, initiate appropriate workup to exclude alternative causes (including infection). Medically manage immune-mediated adverse reactions promptly and refer for specialty consultation as appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Durvalumab may cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with anti-PD-1/PD-L1 monoclonal antibodies. Immune-mediated dermatologic adverse reactions (including grade 3 events) occurred with durvalumab. Immune-mediated dermatologic reactions were treated with systemic corticosteroids, and reactions resolved in over half of patients. Immune-mediated rash and dermatitis have also occurred with durvalumab in combination with tremelimumab, including grade 3 and 4 events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endocrinopathies: Durvalumab is associated with immune-mediated endocrinopathies.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Adrenal insufficiency:</i> Adrenal insufficiency (primary or secondary) may occur. Grade 3 events have been reported (rare). Systemic corticosteroids were administered for adrenal insufficiency; most patients remained on corticosteroid therapy. Withhold or permanently discontinue durvalumab for adrenal insufficiency, depending on the severity. Adrenal insufficiency was also observed (rarely) with durvalumab in combination with tremelimumab, including grade 3 cases.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Diabetes mellitus:</i> Type 1 diabetes mellitus has occurred (which may present with diabetic ketoacidosis), including rare grade 3 events. Long-term insulin therapy has been required in some cases. Hyperglycemia was observed with durvalumab when used in combination with tremelimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Hypophysitis:</i> Durvalumab has been associated with immune-mediated hypophysitis, which may present with acute mass effect symptoms, including headache, photophobia, or visual field defects. Hypophysitis may lead to hypopituitarism. Grade 3 hypophysitis/hypopituitarism occurred rarely; systemic corticosteroids were administered. Hypophysitis/hypopituitarism was also observed (rarely) with durvalumab in combination with tremelimumab.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>- Thyroid disorders:</i> Immune-mediated thyroid disorders have occurred. Depending on severity, immune-mediated thyroid disorders may require treatment interruption or permanent discontinuation. Systemic corticosteroids were required in one-third of patients with hyperthyroidism. Resolution occurred in the majority of patients with hyperthyroidism. Hypothyroidism has occurred, including grade 3 cases. Hypothyroidism may follow hyperthyroidism. Systemic corticosteroids were necessary in some patients, and a majority of patients required long-term thyroid hormone replacement therapy. Thyroiditis may present with or without endocrinopathy. Thyroiditis occurred rarely and did not result in permanent discontinuation of durvalumab. Systemic corticosteroids or endocrine therapy were required in some patients. Thyroiditis, hyperthyroidism, and hypothyroidism have also been observed with durvalumab in combination with tremelimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI adverse effects: Immune-mediated colitis has occurred with durvalumab, including grade 3 or higher cases. Diarrhea is the primary colitis symptom. Systemic corticosteroids were administered for immune-mediated colitis; the majority of patients with colitis experienced resolution. Some patients required other immunosuppressants (rarely) to manage colitis. Cytomegalovirus infection or reactivation has been observed in patients with corticosteroid-refractory, immune-mediated colitis. Pancreatitis (including increased serum amylase and lipase levels), gastritis, and duodenitis have also been reported. Colitis has also been reported with durvalumab in combination with tremelimumab (including grade 3 colitis); intestinal perforation, large intestine perforation, and pancreatitis have been observed with durvalumab in combination with tremelimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Immune-mediated hepatitis has occurred with durvalumab, including grade 3 and fatal cases. Systemic corticosteroids were used to manage immune-mediated hepatitis; resolution occurred in over half of patients. Mycophenolate (in combination with corticosteroids) was used to manage hepatitis rarely. Immune-mediated hepatitis has also been observed with durvalumab in combination with tremelimumab, including grade 3, grade 4, and fatal cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion reactions have been observed with durvalumab, including when used in combination with tremelimumab; severe or life-threatening infusion-related reactions have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Immune-mediated nephritis with renal dysfunction has occurred (rarely), including grade 3 cases. Nephritis was treated with systemic corticosteroids and resolved in most patients. Nephritis has also been reported with durvalumab in combination with tremelimumab (including grade 3 nephritis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Immune-mediated uveitis, iritis, and other ocular inflammatory toxicities may occur with durvalumab. Some cases can be associated with retinal detachment. Differing grades of visual impairment (including blindness) may occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicities: Immune-mediated pneumonitis has been observed (both in patients who did or did not receive prior radiation), including grade 3 and 4 and fatal cases. Pneumonitis incidence is higher in patients who have received prior thoracic radiation. Pneumonitis was managed with systemic corticosteroids in the majority of cases and resolved in approximately half of the affected patients. The frequency and severity of immune-mediated pneumonitis in patients who did not receive definitive chemoradiation prior to durvalumab were similar whether durvalumab was administered as a single agent or in combination with chemotherapy. Pneumonitis has also been observed with durvalumab when used in combination with tremelimumab, including grade 3 and fatal cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Other immune-mediated toxicities: Other clinically relevant immune-mediated disorders have been observed rarely with durvalumab (or other anti-PD-1/PD-L1 monoclonal antibodies) and may affect any organ system (may be fatal), including myocarditis, pericarditis, vasculitis, meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy, myositis/polymyositis, rhabdomyolysis (and associated sequelae including renal failure), arthritis, polymyalgia rheumatic, hypoparathyroidism, hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, and solid organ transplant rejection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic stem cell transplant: Fatal and other serious complications may occur in patients who received allogeneic hematopoietic stem cell transplant (HSCT) before or after treatment with an anti-PD-1/PD-L1 monoclonal antibody. Transplant-related complications may include hyperacute graft-versus-host disease (GVHD), acute or chronic GVHD, hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome) after reduced-intensity conditioning, and steroid-requiring febrile syndrome (with no identified infectious etiology). These complications may occur despite intervening therapy between durvalumab and HSCT. Manage early signs/symptoms of transplant-related complications promptly. Assess the risks/benefits of treatment with an anti-PD-1/PD-L1 monoclonal antibody prior to or after an allogenic HSCT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Checkpoint inhibitors may worsen or precipitate new myasthenia gravis (MG), especially within the first 16 weeks of treatment; use with caution. Patients with well-controlled MG may be considered for checkpoint inhibitor therapy if MG treatment is maintained (or reinitiated in patients whose MG is in remission), combination therapy (eg, anti–CTLA-4 with anti–PD-a/PD-L1 monoclonal antibodies) is avoided, and respiratory and bulbar function are closely followed. In patients who develop overt MG during checkpoint inhibitor therapy, early aggressive treatment with plasma exchange or IVIG in combination with high-dose corticosteroids may be required (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F50081303"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imfinzi: 120 mg/2.4 mL (2.4 mL); 500 mg/10 mL (10 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F50081301"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F50170425"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Imfinzi Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120MG/2.4ML (per mL): $483.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/10 mL (per mL): $483.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872277"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imfinzi: 50 mg/mL (2.4 mL, 10 mL) [contains polysorbate 80]</p></div>
<div class="block accres drugH1Div" id="F57439142"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Imfinzi is available through specialty pharmacy providers and distributors. Information is available at https://www.myaccess360.com/content/dam/website-services/us/552-access360/hcp-pdf/DURVALUMAB_Distribution_Sheet.pdf.</p></div>
<div class="block adm drugH1Div" id="F50135402"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over 60 minutes through an IV line containing a sterile, low-protein binding 0.2 or 0.22 micron in-line filter. Administer all concomitant combination medications as separate IV infusions; do not administer other medications through the same IV line.</p>
<p style="text-indent:-2em;margin-left:2em;">Combination regimens:</p>
<p style="text-indent:-2em;margin-left:4em;">Use separate infusion bags and filters for each medication.</p>
<p style="text-indent:-2em;margin-left:4em;">When used in combination with chemotherapy, administer durvalumab prior to chemotherapy on the same day.</p>
<p style="text-indent:-2em;margin-left:4em;">When used in combination with tremelimumab, administer tremelimumab first and observe patient for 60 minutes following completion of tremelimumab, then administer durvalumab on the same day.</p>
<p style="text-indent:-2em;margin-left:4em;">When used in combination with tremelimumab and platinum-based chemotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">Cycle 1: Administer tremelimumab first; 1 to 2 hours after completion of tremelimumab infusion, administer durvalumab over 60 minutes, then administer platinum-based chemotherapy 1 to 2 hours after the completion of the durvalumab infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Subsequent cycles: If no infusion reactions occur in cycle 1, durvalumab may be administered immediately following tremelimumab and the time between the end of the durvalumab infusion and the start of chemotherapy may be reduced to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">When used in combination with tremelimumab and pemetrexed, administer tremelimumab first, followed by durvalumab and then pemetrexed on the day of dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for infusion reactions. Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions (consider premedications with subsequent infusions); discontinue permanently for grade 3 or 4 reactions.</p></div>
<div class="block meg drugH1Div" id="F50046857"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Imfinzi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761069s042lbl.pdf%23page%3D51&amp;token=wQ9aLTIaWwxzKnxMeFQi%2BL1s%2B7Vhr12BI%2BBodIj3vW5f5KSO4IpnQMaxgiA7pxNWFayzpUpmQ5ocRBBL62UXdTxZe8WY4aMDQhS5Rj7lNLfmcudfhxEpQI5fqEWWvUXL&amp;TOPIC_ID=112994" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761069s042lbl.pdf#page=51</a></p></div>
<div class="block use drugH1Div" id="F50027746"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, locally advanced or metastatic: </b>Treatment of locally advanced or metastatic biliary tract cancer (in combination with gemcitabine and cisplatin) in adults.<b></b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma, unresectable: </b>Treatment of unresectable hepatocellular carcinoma (in combination with tremelimumab) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of unresectable stage 3 non–small cell lung cancer (NSCLC) in adults whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of metastatic NSCLC (in combination with tremelimumab and platinum-based chemotherapy) in adults whose tumors have no sensitizing epidermal growth factor receptor mutations or anaplastic lymphoma kinase genomic tumor aberrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, extensive stage:</b> First-line treatment of extensive-stage small cell lung cancer (in combination with etoposide and either carboplatin or cisplatin) in adults.</p></div>
<div class="block mst drugH1Div" id="F50135314"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Durvalumab be confused with atezolizumab, avelumab, daratumumab, denosumab, dinutuximab, dostarlimab, duvelisib, emapalumab, nivolumab, pembrolizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Imfinzi may be confused with Imjudo.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50101820"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50101817"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies) may enhance the hepatotoxic effect of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53540838"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to durvalumab treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during therapy and for 3 months after the last durvalumab dose.</p></div>
<div class="block pri drugH1Div" id="F50135321"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, and data from animal reproduction studies, in utero exposure to durvalumab may cause fetal harm. Durvalumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F50135322"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if durvalumab is present in breast milk; however, endogenous immunoglobulins are excreted in breast milk. Due to the potential for adverse events in a breastfed infant, breastfeeding is not recommended by the manufacturer during therapy or for 3 months after the last durvalumab dose.</p></div>
<div class="block mop drugH1Div" id="F50135414"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor liver function; renal (creatinine); thyroid function tests (at baseline, periodically during treatment); blood glucose (for hyperglycemia). Verify pregnancy status prior to durvalumab initiation in patients who could become pregnant. Monitor closely for clinical signs/symptoms of immune-mediated adverse reactions, including adrenal insufficiency, colitis/diarrhea (consider initiating or repeating infectious workup in patients with corticosteroid-refractory immune-mediated colitis to exclude alternative causes), dermatologic toxicity, diabetes/hyperglycemia, hepatitis/hepatotoxicity, hypophysitis or hypopituitarism, pneumonitis, ocular toxicity, and thyroid disorders. Monitor for signs/symptoms of infusion reactions. If received/receiving hematopoietic stem cell transplant, monitor closely for early signs/symptoms of transplant-related complications.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]). Obtain baseline ECG, natriuretic peptides, and troponins in all patients; obtain a baseline echocardiogram in high-risk patients; consider serial ECGs and cardiac troponins prior to doses 2, 3, and 4, and if normal, reduce to every 3 doses until completion of therapy; cardiovascular risk assessment every 6 to 12 months in high-risk patients who require long-term therapy (&gt;12 months therapy, consider cardiovascular risk assessment every 6 to 12 months in all patients requiring long-term therapy) (ESC [Lyon 2022]). Refer to a cardiologist when clinically indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional suggested monitoring (ASCO [Schneider 2021):</p>
<p style="text-indent:-2em;margin-left:4em;">Prior to therapy: CBC with differential, serum chemistries, creatine kinase; comprehensive clinical assessment including performance status, weight, body mass index, heart rate, blood pressure, and oxygen saturation; consider chest x-ray, electrocardiogram, and CT scan; assess history of autoimmune conditions, organ-specific disease, endocrinopathies, neuropathy, and infectious disease; assess bowel habits, respiratory symptoms, skin (for rash), arthralgias, and neurologic symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">During therapy: Assess blood pressure, weight, heart rate, and oxygen saturation; assess for infections, screen for hyperglycemia/diabetes (polyuria, polydipsia, weight loss); eye exam (including intraocular pressure after 6 weeks), CBC with differential, serum chemistries, and creatine kinase; monitor bone mineral density (with long-term therapy).</p></div>
<div class="block pha drugH1Div" id="F50135385"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody which blocks programmed cell death ligand 1 (PD-L1) binding to PD-1 and CD80 (B7.1); PD-L1 blockade leads to increased T-cell activation, allowing T-cells to kill tumor cells (Massard 2016). PD-L1 is an immune check point protein expressed on tumor cells and tumor infiltrating cells and down regulates anti-tumor t-cell function by binding to PD-1 and B7.1; blocking PD-1 and B7.1 interactions restores antitumor t-cell function (Fehrenbacher 2016; Rosenberg 2016).</p></div>
<div class="block phk drugH1Div" id="F50135386"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The steady state AUC, C<sub>trough</sub>, and C<sub>max</sub> in patients who received 1,500 mg once every 4 weeks are 6% higher, 19% lower, and 55% higher (respectively) compared to those who received 10 mg/kg once every 2 weeks. Based on pharmacokinetic modeling data and safety exposure relationships, there are no anticipated clinically meaningful differences in efficacy and safety for 1,500 mg once-every-4-weeks doses compared to 10 mg/kg once-every-2-weeks doses in patients weighing &gt;30 kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 5.4 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: Terminal half-life: ~21 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Steady-state clearance: 8 mL/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F51192308"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Imfinzio</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Imfinzi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-35989744">
<a name="35989744"></a>Abidoye O, Kim N, Fombi J. An interesting case report of myasthenia gravis exacerbation induced by durvalumab. <i>Cureus</i>. 2022;14(7):e26985. doi:10.7759/cureus.26985<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/35989744/pubmed" id="35989744" target="_blank">35989744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abou-Alfa.1">
<a name="Abou-Alfa.1"></a>Abou-Alfa G, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. https://evidence.nejm.org/doi/10.1056/EVIDoa2100070 . Published June 6, 2022. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28885881">
<a name="28885881"></a>Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. <i>N Engl J Med.</i> 2017;377(20):1919-1929.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/28885881/pubmed" id="28885881" target="_blank">28885881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280658">
<a name="30280658"></a>Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. <i>N Engl J Med</i>. 2018;379(24):2342-2350. doi:10.1056/NEJMoa1809697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/30280658/pubmed" id="30280658" target="_blank">30280658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32420087">
<a name="32420087"></a>Casafont-Solé I, Martínez-Morillo M, Camins-Fàbregas J, Brandy-García A, Quer A, Moran T. IgA vasculitis and polymyalgia rheumatica induced by durvalumab. <i>Transl Lung Cancer Res</i>. 2020;9(2):421-423. doi:10.21037/tlcr.2020.03.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/32420087/pubmed" id="32420087" target="_blank">32420087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34053457">
<a name="34053457"></a>Cham J, Ng D, Nicholson L. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report. <i>J Med Case Rep</i>. 2021;15(1):278. doi:10.1186/s13256-021-02858-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34053457/pubmed" id="34053457" target="_blank">34053457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34188921">
<a name="34188921"></a>Dougherty SC, Lynch AC, Hall RD. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. <i>Clin Case Rep</i>. 2021;9(6):e04227. doi:10.1002/ccr3.4227<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34188921/pubmed" id="34188921" target="_blank">34188921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26970723">
<a name="26970723"></a>Fehrenbacher L, Spira A, Ballinger M, et al; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i>. 2016;387(10030):1837-1846. doi: 10.1016/S0140-6736(16)00587-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/26970723/pubmed" id="26970723" target="_blank">26970723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33615756">
<a name="33615756"></a>Huang S, Bai X, Fang T, Guo Y, Zheng K, Lin X. Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database. <i>J Zhejiang Univ Sci B</i>. 2021;22(2):156-164. doi:10.1631/jzus.B2000449<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/33615756/pubmed" id="33615756" target="_blank">33615756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imfinzi.1">
<a name="Imfinzi.1"></a>Imfinzi (durvalumab) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imfinzi.2">
<a name="Imfinzi.2"></a>Imfinzi (durvalumab) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327426">
<a name="36327426"></a>Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. <i>J Clin Oncol.</i> 2023;41(6):1213-1227. doi:10.1200/JCO.22.00975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/36327426/pubmed" id="36327426" target="_blank">36327426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34408921">
<a name="34408921"></a>Landman Y, Jacobi O, Kurman N, et al. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer. <i>Oncoimmunology</i>. 2021;10(1):1959979. doi:10.1080/2162402X.2021.1959979<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34408921/pubmed" id="34408921" target="_blank">34408921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35046822">
<a name="35046822"></a>Liu W, Chen B, Liu Y, Luo Z, Sun B, Ma F. Durvalumab-induced demyelinating lesions in a patient with extensive-stage small-cell lung cancer: a case report. <i>Front Pharmacol</i>. 2022;12:799728. doi:10.3389/fphar.2021.799728<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/35046822/pubmed" id="35046822" target="_blank">35046822</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35866825">
<a name="35866825"></a>Malet J, Melki B, Chouabe S, Deslée G. Immune-related pancreatitis due to anti-PD-L1 therapy in a patient with non-small cell lung cancer: a case report. <i>Medicine (Baltimore)</i>. 2022;101(29):e29612. doi:10.1097/MD.0000000000029612<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/35866825/pubmed" id="35866825" target="_blank">35866825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27269937">
<a name="27269937"></a>Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. <i>J Clin Oncol</i>. 2016;34(26):3119-3125. doi:10.1200/JCO.2016.67.9761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/27269937/pubmed" id="27269937" target="_blank">27269937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31310083">
<a name="31310083"></a>Mengíbar JL, Capel I, Bonfill T, et al. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment. <i>Endocrinol Diabetes Metab Case Rep</i>. 2019;2019(1):19-0045. doi:10.1530/EDM-19-0045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/31310083/pubmed" id="31310083" target="_blank">31310083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oh.1">
<a name="Oh.1"></a>Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemsitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. American Society of Clinical Oncology. https://d32wbias3z7pxg.cloudfront.net/meeting/286/abstract/pdf/286-14141-204876.pdf. Accessed June 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34980792">
<a name="34980792"></a>Otohara M, Kawamoto K, Tanaka Y, Taniwaki M. Durvalumab-induced severe gastritis. <i>Intern Med</i>. 2022;61(14):2239-2240. doi:10.2169/internalmedicine.8292-21<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34980792/pubmed" id="34980792" target="_blank">34980792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31829972">
<a name="31829972"></a>Patel S, Chin V, Greenfield JR. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism. <i>Endocrinol Diabetes Metab Case Rep</i>. 2019;2019:19-0098. doi:10.1530/EDM-19-0098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/31829972/pubmed" id="31829972" target="_blank">31829972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31590988">
<a name="31590988"></a>Paz-Ares L, Dvorkin M, Chen Y, et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i>. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/31590988/pubmed" id="31590988" target="_blank">31590988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32971005">
<a name="32971005"></a>Powles T, van der Heijden MS, Castellano D, et al; DANUBE study investigators. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncol</i>. 2020;21(12):1574-1588. doi:10.1016/S1470-2045(20)30541-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/32971005/pubmed" id="32971005" target="_blank">32971005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26952546">
<a name="26952546"></a>Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet.</i> 2016;387(10031):1909-1920. doi: 10.1016/S0140-6736(16)00561-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/26952546/pubmed" id="26952546" target="_blank">26952546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32110415">
<a name="32110415"></a>Sanderson E, Wimaleswaran H, Senko C, White S, McDonald CF. Durvalumab induced sarcoid-like pulmonary lymphadenopathy. <i>Respirol Case Rep</i>. 2020;8(3):e00542. doi:10.1002/rcr2.542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/32110415/pubmed" id="32110415" target="_blank">32110415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34249743">
<a name="34249743"></a>Shionoya Y, Hattori A, Hanada T, Fujino M. Case report: durvalumab-associated encephalitis in extensive-stage small cell lung carcinoma. <i>Front Oncol</i>. 2021;11:693279. doi:10.3389/fonc.2021.693279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34249743/pubmed" id="34249743" target="_blank">34249743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35412706">
<a name="35412706"></a>Vrabic N, Fakin A, Mekjavic PJ, Janzic U, Vrankar M, Valentincic NV. Various clinical presentations of uveitis associated with durvalumab treatment. <i>Radiol Oncol</i>. 2022;56(2):129-137. doi:10.2478/raon-2022-0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/35412706/pubmed" id="35412706" target="_blank">35412706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34287773">
<a name="34287773"></a>Wang L, Lou H, Li B, Li J, Yang YM. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. <i>Invest New Drugs</i>. 2022;40(1):151-156. doi:10.1007/s10637-021-01154-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/durvalumab-drug-information/abstract-text/34287773/pubmed" id="34287773" target="_blank">34287773</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 112994 Version 131.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
